{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:41:13Z","timestamp":1791232873032,"version":"4.1.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Department of 1090 Defense Breast Program"},{"name":"SU2C (AACR)","award":["SU2C-AACR-DT0409"],"award-info":[{"award-number":["SU2C-AACR-DT0409"]}]},{"name":"Lombardi Comprehensive Cancer 1095 Center Support Grant (CCSG)","award":["P30 CA051008"],"award-info":[{"award-number":["P30 CA051008"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","maturitas.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Maturitas"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.maturitas.2011.09.006","type":"journal-article","created":{"date-parts":[[2011,10,12]],"date-time":"2011-10-12T13:22:39Z","timestamp":1318425759000},"page":"315-321","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["Progress in endocrine approaches to the treatment and prevention of breast cancer"],"prefix":"10.1016","volume":"70","author":[{"given":"Ifeyinwa","family":"Obiorah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. Craig","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.maturitas.2011.09.006_bib0005","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S0140-6736(01)72307-0","article-title":"On the treatment of inoperable cases of carcinoma of the mamma. Suggestions for a new method of treatment with illustrative cases","volume":"2","author":"Beatson","year":"1896","journal-title":"Lancet"},{"key":"10.1016\/j.maturitas.2011.09.006_bib0010","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1158\/0008-5472.CAN-09-0029","article-title":"A century of deciphering the control mechanisms of sex steroid action in breast and prostate cancer: the origins of targeted therapy and chemoprevention","volume":"69","author":"Jordan","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.maturitas.2011.09.006_bib0015","doi-asserted-by":"crossref","first-page":"S269","DOI":"10.1038\/sj.bjp.0706399","article-title":"Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer","volume":"147","author":"Jordan","year":"2006","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.maturitas.2011.09.006_bib0020","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nrd1031","article-title":"Tamoxifen: a most unlikely pioneering medicine","volume":"2","author":"Jordan","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.maturitas.2011.09.006_bib0025","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ejca.2007.11.002","article-title":"Tamoxifen: catalyst for the change to targeted therapy","volume":"44","author":"Jordan","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.maturitas.2011.09.006_bib0030","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1002\/1097-0142(20011101)92:9<2247::AID-CNCR1570>3.0.CO;2-Y","article-title":"Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma","volume":"92","author":"Bonneterre","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.maturitas.2011.09.006_bib0035","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1200\/JCO.2003.04.194","article-title":"Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group","volume":"21","author":"Mouridsen","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.maturitas.2011.09.006_bib0040","doi-asserted-by":"crossref","first-page":"4883","DOI":"10.1200\/JCO.2007.14.4659","article-title":"Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group","volume":"26","author":"Paridaens","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.maturitas.2011.09.006_bib0045","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.clbc.2011.06.003","article-title":"Aromatase inhibitor versus tamoxifen in postmenopausal woman with advanced breast cancer: a literature-based meta-analysis","volume":"11","author":"Xu","year":"2011","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.maturitas.2011.09.006_bib0050","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","article-title":"Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials","volume":"378","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.maturitas.2011.09.006_bib0055","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S1470-2045(10)70257-6","article-title":"Effect of anastrozole and tamoxifen as adjuvant treatment for early stage breast cancer: 10-year analysis of the ATAC trial","volume":"11","author":"Cuzick","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.maturitas.2011.09.006_bib0060","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1056\/NEJMoa0810818","article-title":"Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer","volume":"361","author":"Mouridsen","year":"2009","journal-title":"N Engl J Med"},{"issue":"Suppl.","key":"10.1016\/j.maturitas.2011.09.006_bib0065","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1158\/0008-5472.SABCS-15","article-title":"Results of the first planned analysis of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer","volume":"69","author":"Jones","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.maturitas.2011.09.006_bib0070","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1200\/JCO.2009.23.1274","article-title":"Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen","volume":"28","author":"Dowsett","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.maturitas.2011.09.006_bib0075","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0140-6736(05)67059-6","article-title":"Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years\u2019 adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial","volume":"366","author":"Jakesz","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.maturitas.2011.09.006_bib0080","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/cncr.23171","article-title":"Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer","volume":"112","author":"Cuppone","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.maturitas.2011.09.006_bib0085","doi-asserted-by":"crossref","first-page":"vii10","DOI":"10.1093\/annonc\/mdl941","article-title":"Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial","volume":"17","author":"Boccardo","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.maturitas.2011.09.006_bib0090","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0140-6736(07)60200-1","article-title":"Survival and safety of exemestane versus tamoxifen after 2\u20133 years\u2019 tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial","volume":"369","author":"Coombes","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.maturitas.2011.09.006_bib0095","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1200\/JCO.2006.08.8054","article-title":"Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study","volume":"25","author":"Kaufmann","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.maturitas.2011.09.006_bib0100","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0140-6736(10)62312-4","article-title":"Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial","volume":"377","author":"van de Velde","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.maturitas.2011.09.006_bib0105","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1200\/JCO.2009.26.3756","article-title":"American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer","volume":"28","author":"Burstein","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.maturitas.2011.09.006_bib0110","doi-asserted-by":"crossref","first-page":"6330","DOI":"10.1158\/1078-0432.CCR-07-5221","article-title":"Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels","volume":"14","author":"Geisler","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.maturitas.2011.09.006_bib0115","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1016\/S0959-8049(03)00630-0","article-title":"An open randomised trial of second-line endocrine therapy in advanced breast cancer: comparison of the aromatase inhibitors letrozole and anastrozole","volume":"39","author":"Rose","year":"2003","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.maturitas.2011.09.006_bib0120","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1200\/JCO.2010.31.6950","volume":"29","author":"Ellis","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.maturitas.2011.09.006_bib0125","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa032312","article-title":"A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early stage breast cancer","volume":"349","author":"Goss","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.maturitas.2011.09.006_bib0130","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1093\/annonc\/mdm566","article-title":"Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17","volume":"19","author":"Ingle","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.maturitas.2011.09.006_bib0135","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1093\/jnci\/djm246","article-title":"Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a","volume":"99","author":"Jakesz","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.maturitas.2011.09.006_bib0140","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1200\/JCO.2007.14.0228","article-title":"Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial","volume":"26","author":"Mamounas","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.maturitas.2011.09.006_bib0145","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1200\/JCO.2010.32.2933","article-title":"Long-term benefits of 5 years of tamoxifen: 10-year follow-up of a large randomized trial in women at least 50 years of age with early breast cancer","volume":"29","author":"Hackshaw","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.maturitas.2011.09.006_bib0150","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1476-5381.1986.tb10174.x","article-title":"antioestrogenic actions in a series of triphenylbut-1-enes: modulation of prolactin synthesis in vitro","volume":"87","author":"Jordan","year":"1986","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.maturitas.2011.09.006_bib0155","doi-asserted-by":"crossref","first-page":"4741","DOI":"10.1016\/S0021-9258(18)32484-0","article-title":"An estrogen receptor model to describe the regulation of prolactin synthesis by antiestrogens in vitro","volume":"258","author":"Lieberman","year":"1983","journal-title":"J Biol Chem"},{"key":"10.1016\/j.maturitas.2011.09.006_bib0160","first-page":"1870","article-title":"Species-specific pharmacology of antiestrogens: role of metabolism","volume":"46","author":"Jordan","year":"1987","journal-title":"Fed Proc"},{"key":"10.1016\/j.maturitas.2011.09.006_bib0165","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/BF01806132","article-title":"Effects of anti-estrogens on bone in castrated and intact female rats","volume":"10","author":"Jordan","year":"1987","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.maturitas.2011.09.006_bib0170","first-page":"4020","article-title":"Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model","volume":"47","author":"Gottardis","year":"1987","journal-title":"Cancer Res"},{"key":"10.1016\/j.maturitas.2011.09.006_bib0175","first-page":"812","article-title":"Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse","volume":"48","author":"Gottardis","year":"1988","journal-title":"Cancer Res"},{"key":"10.1016\/j.maturitas.2011.09.006_bib0180","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(89)91141-0","article-title":"Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers","volume":"1","author":"Fornander","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.maturitas.2011.09.006_bib0185","first-page":"4177","article-title":"Development of antiestrogens and their use in breast cancer: eighth Cain memorial award lecture","volume":"50","author":"Lerner","year":"1990","journal-title":"Cancer Res"},{"key":"10.1016\/j.maturitas.2011.09.006_bib0190","series-title":"Case Histories: Raloxifene","article-title":"Comprehensive medicinal chemistry","author":"Lewis","year":"2006"},{"key":"10.1016\/j.maturitas.2011.09.006_bib0195","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1172\/JCI116985","article-title":"Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats","volume":"93","author":"Black","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1016\/j.maturitas.2011.09.006_bib0200","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.maturitas.2011.09.006_bib0205","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1001\/jama.281.23.2189","article-title":"The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple outcomes of Raloxifene evaluation","volume":"281","author":"Cummings","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.maturitas.2011.09.006_bib0210","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1001\/jama.295.23.joc60074","article-title":"Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial","volume":"295","author":"Vogel","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.maturitas.2011.09.006_bib0215","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa062462","article-title":"Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women","volume":"355","author":"Barrett-Connor","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.maturitas.2011.09.006_bib0220","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1158\/1940-6207.CAPR-10-0076","article-title":"Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 trial: preventing breast cancer","volume":"3","author":"Vogel","year":"2010","journal-title":"Cancer Prev Res"},{"key":"10.1016\/j.maturitas.2011.09.006_bib0225","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1093\/jnci\/djh319","article-title":"Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene","volume":"96","author":"Martino","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.maturitas.2011.09.006_bib0230","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1749-6632.2001.tb04039.x","article-title":"Developing a SERM: stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation","volume":"949","author":"Komm","year":"2001","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.maturitas.2011.09.006_bib0235","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1210\/endo.139.4.5902","article-title":"Effects of CP-336,156, a new, nonsteroidal estrogen agonist\/antagonist, on bone, serum cholesterol, uterus and body composition in rat models","volume":"139","author":"Ke","year":"1998","journal-title":"Endocrinology"},{"key":"10.1016\/j.maturitas.2011.09.006_bib0240","first-page":"F429","article-title":"Lasofoxifene increased BMD of the spine and hip and decreased bone turnover markers in postmenopausal women with low or normal BMD","volume":"20","author":"McClung","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.maturitas.2011.09.006_bib0245","first-page":"S173","article-title":"Extraskeletal effects of lasofoxifene on postmenopausal women","volume":"20","author":"Davidson","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.maturitas.2011.09.006_bib0250","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1345\/aph.1P604","article-title":"Lasofoxifene: selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis","volume":"45","author":"Peterson","year":"2011","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.maturitas.2011.09.006_bib0255","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1056\/NEJMoa0808692","article-title":"Lasofoxifene in postmenopausal women with osteoporosis","volume":"362","author":"Cummings","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.maturitas.2011.09.006_bib0260","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1093\/jnci\/djq415","article-title":"Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women","volume":"102","author":"LaCroix","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.maturitas.2011.09.006_bib0265","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/01.gme.0000188736.69617.4f","article-title":"Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene","volume":"13","author":"McClung","year":"2006","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2011.09.006_bib0270","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1359\/jbmr.071206","article-title":"Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study","volume":"23","author":"Miller","year":"2008","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.maturitas.2011.09.006_bib0275","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1359\/jbmr.080710","article-title":"Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial","volume":"23","author":"Silverman","year":"2008","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.maturitas.2011.09.006_bib0280","article-title":"Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study","author":"Silverman","year":"2011","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.maturitas.2011.09.006_bib0285","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.bone.2009.02.014","article-title":"Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX","volume":"44","author":"Kanis","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.maturitas.2011.09.006_bib0290","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.fertnstert.2009.05.094","article-title":"Endometrial effects of a tissue selective estrogen complex containing bazedoxifene\/conjugated estrogens as a menopausal therapy","volume":"92","author":"Pickar","year":"2009","journal-title":"Fertil Steril"},{"key":"10.1016\/j.maturitas.2011.09.006_bib0295","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.fertnstert.2009.02.093","article-title":"Efficacy of tissue-selective estrogen complex of bazedoxifene\/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women","volume":"92","author":"Lindsay","year":"2009","journal-title":"Fertil Steril"},{"key":"10.1016\/j.maturitas.2011.09.006_bib0300","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s11914-010-0025-0","article-title":"New selective estrogen receptor modulators (SERMs) in development","volume":"8","author":"Silverman","year":"2010","journal-title":"Curr Osteoporos Rep"},{"key":"10.1016\/j.maturitas.2011.09.006_bib0305","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/gme.0b013e3181c1ac01","article-title":"Group aTOS. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study","volume":"17","author":"Bachmann","year":"2010","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2011.09.006_bib0310","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1056\/NEJMoa1103507","article-title":"Exemestane for breast-cancer prevention in postmenopausal women","volume":"364","author":"Goss","year":"2011","journal-title":"N Engl J Med"}],"container-title":["Maturitas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512211003252?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512211003252?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T08:53:23Z","timestamp":1759913603000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378512211003252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":62,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S0378512211003252"],"URL":"https:\/\/doi.org\/10.1016\/j.maturitas.2011.09.006","relation":{},"ISSN":["0378-5122"],"issn-type":[{"value":"0378-5122","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progress in endocrine approaches to the treatment and prevention of breast cancer","name":"articletitle","label":"Article Title"},{"value":"Maturitas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.maturitas.2011.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}